Interleukin-16 enhances anti-tumor immune responses by establishing a Th1 cell-macrophage crosstalk through reprogramming glutamine metabolism in mice
Open Access
- 10 March 2025
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-17
Abstract
Overcoming immunosuppression in the tumor microenvironment (TME) is crucial for developing novel cancer immunotherapies. Here, we report that IL-16 administration enhances the polarization of T helper 1 (Th1) cells by inhibiting glutamine catabolism through the downregulation of glutaminase in CD4+ T cells and increases the production of Th1 effector cytokine IFN-γ, thus improving anti-tumor immune responses. Moreover, we find that establishing an IL-16-dependent, Th1-dominant TME relies on mast cell-produced histamine and results in the increased expression of the CXCR3 ligands in tumor-associated macrophages (TAM), thereby improving the therapeutic effectiveness of immune checkpoint blockade (ICB). Cancer patients exhibit impaired production of IL-16, which correlates with poorer prognosis. Additionally, low IL-16 production is associated with unresponsiveness to immunotherapy in cancer patients. Collectively, our findings provided new insights into the biological function of IL-16, emphasizing its potential clinical significance as a therapeutic approach to augment anti-tumor immunity and sensitize ICB-based cancer immunotherapy.Keywords
Funding Information
- National Natural Science Foundation of China (82171730, 82272872, 81970484, 81930041, U22A20307)
- Natural Science Foundation of Zhejiang Province (LY22H160003)
This publication has 58 references indexed in Scilit:
- MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cellsCancer Cell, 2022
- The role of GSK3 in metabolic pathway perturbations in cancerBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2021
- Role of Mast Cells in Shaping the Tumor MicroenvironmentClinical Reviews in Allergy & Immunology, 2020
- The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell CarcinomaCancer Cell, 2018
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic MelanomaCell, 2017
- Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell ResponsesCell, 2015
- Glycogen synthase kinase‐3 controls IL‐10 expression in CD4+ effector T‐cell subsets through epigenetic modification of the IL‐10 promoterEuropean Journal of Immunology, 2015
- The association of interleukin-16 gene polymorphisms with IL-16 serum levels and risk of nasopharyngeal carcinoma in a Chinese populationTumor Biology, 2013
- Posttranscriptional Control of T Cell Effector Function by Aerobic GlycolysisCell, 2013
- Interleukin-16Journal of Leukocyte Biology, 2000